Clinical Trials Directory

Trials / Completed

CompletedNCT01774838

Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
49 (actual)
Sponsor
University of Cologne · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

To test the vasoactive and anti-inflammatory effects of prasugrel in patients with acute coronary syndrome endothelial function -as a surrogate parameter of NO bioavailability- and different markers of inflammation, oxidative stress and platelet activation will be assessed in patients with unstable angina.

Detailed description

Trial Objectives To test the vasoactive and anti-inflammatory effects of prasugrel in patients with acute coronary syndrome, endothelial function -as a surrogate parameter of NO bioavailability- and different markers of inflammation, oxidative stress and platelet activation will be assessed in patients with unstable angina. Trial Design Single center, double blind, double-dummy, randomized, parallel trial. Endpoints Primary Endpoint Assessment of endothelial function (FMD) via high-resolution ultrasound (Sonoline G50, 12 MHz linear array transducer, Siemens, Germany) by experienced sonographer. Secondary Endpoints * Non-invasive assessment of microvascular perfusion and oxygen saturation by laser Doppler perfusion imaging and tissue spectrometry (O2C, Lea Medizintechnik, Giessen, Germany) * Determination of leukocyte activity: plasma MPO levels (ELISA), plasma elastase levels (ELISA) * Assessment of platelet activity: plasma levels of sCD40 ligand (ELISA), RANTES (ELISA) * Measurement of different oxidative stress markers: hsCRP (ELISA), CD40 ligand (ELISA), carbonylated proteins (ELISA), urinary 8-iso-PGF2α (gas chromatography mass spectrometry) * Determination of platelet-leukocyte aggregates by fluorescent activated cell sorter (FACS) * Assessment of platelet function (PADA-test)

Conditions

Interventions

TypeNameDescription
DRUGPrasugrel3 months treatment
DRUGClopidogrel3 months treatment

Timeline

Start date
2014-10-01
Primary completion
2015-06-01
Completion
2015-06-01
First posted
2013-01-24
Last updated
2015-06-11

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT01774838. Inclusion in this directory is not an endorsement.